Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
1.64
USD
-4.09%
-14.81%
-30.51%
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Index
June 23, 2023 at 12:00 am EDT
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Index
Transcript : GlycoMimetics, Inc., Q4 2023 Earnings Call, Mar 27, 2024
Mar. 27
GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 27
CI
GlycoMimetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 27
CI
North American Morning Briefing : Stocks Edge -2-
Mar. 27
DJ
GlycoMimetics, Inc. Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1A Healthy Volunteer Study of GMI-1687
Jan. 04
CI
GlycoMimetics, Thermo Fisher Unit Set Accord for Manufacturing Uproleselan for Acute Myeloid Leukemia
Jan. 02
MT
Capital One Initiates GlycoMimetics With Overweight Rating, Price Target is $12
Dec. 22
MT
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 03
CI
Transcript : GlycoMimetics, Inc., Q3 2023 Earnings Call, Nov 03, 2023
Nov. 03
GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
23-09-06
CI
Transcript : GlycoMimetics, Inc., Q2 2023 Earnings Call, Aug 02, 2023
23-08-02
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-02
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Growth Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Value Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Value Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Growth Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Index
23-06-23
CI
GlycoMimetics Says FDA Approves Time-Based Analysis of Overall Survival in Phase 3 Acute Myeloid Leukemia Study
23-06-15
MT
GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
23-06-15
CI
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-03
CI
Transcript : GlycoMimetics, Inc., Q1 2023 Earnings Call, May 03, 2023
23-05-03
North American Morning Briefing : Traders Await -2-
23-05-03
DJ
Transcript : GlycoMimetics, Inc., Q4 2022 Earnings Call, Mar 29, 2023
23-03-29
North American Morning Briefing : Investor Mood -3-
23-03-29
DJ
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
More about the company
Last Close Price
1.64
USD
Average target price
7
USD
Spread / Average Target
+326.83%
Consensus
1st Jan change
Capi.
-30.51% 106M -2.31% 103B +0.56% 95.28B +1.69% 22.15B -17.37% 21.02B -9.30% 18.15B -41.01% 16.74B -14.85% 16.05B +3.21% 13.68B +33.54% 12.17B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
GLYCOMIMETICS, INC. 
